Musa Tariq Sells 2,320 Shares of Guardant Health, Inc. (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 2,320 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the sale, the director now owns 2,676 shares in the company, valued at approximately $93,660. The trade was a 46.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Guardant Health Trading Down 2.2 %

GH opened at $34.84 on Wednesday. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.85 and a current ratio of 6.22. The stock’s 50 day moving average price is $28.21 and its 200-day moving average price is $28.21. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $38.53. The stock has a market cap of $4.30 billion, a price-to-earnings ratio of -8.22 and a beta of 1.26.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The business had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. During the same period last year, the company earned ($0.73) EPS. The business’s revenue was up 33.9% compared to the same quarter last year. On average, equities analysts forecast that Guardant Health, Inc. will post -3.44 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Cerity Partners LLC increased its holdings in Guardant Health by 54.6% during the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock worth $4,473,000 after purchasing an additional 68,883 shares during the period. Lord Abbett & CO. LLC bought a new position in shares of Guardant Health during the 3rd quarter worth $15,624,000. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Guardant Health by 1,282.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock valued at $28,128,000 after buying an additional 1,137,482 shares during the period. First Light Asset Management LLC raised its holdings in shares of Guardant Health by 119.7% in the second quarter. First Light Asset Management LLC now owns 416,967 shares of the company’s stock valued at $12,042,000 after acquiring an additional 227,202 shares in the last quarter. Finally, Pier Capital LLC lifted its stake in Guardant Health by 36.7% in the third quarter. Pier Capital LLC now owns 158,429 shares of the company’s stock worth $3,634,000 after acquiring an additional 42,575 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on GH. JPMorgan Chase & Co. increased their target price on Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Leerink Partners cut their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. UBS Group lifted their price objective on shares of Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, August 21st. The Goldman Sachs Group lifted their target price on Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, Sanford C. Bernstein lowered their price objective on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. Fifteen research analysts have rated the stock with a buy rating, According to MarketBeat.com, Guardant Health has a consensus rating of “Buy” and an average price target of $40.60.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.